Voting Rights and Capital

15 December 2006

In conformity with the Transparency Directive's transitional provision 6 the directors of LiDCO Group plc would like to notify the market that LiDCO’s issued share capital consists of 118,096,850 ordinary shares of 0.5p each as at the date of this announcement. No ordinary shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, LiDCO Group plc under the FSA's Disclosure and Transparency Rules.

Notes for Editors

About LiDCO Group Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London.

The Company's manufacturing facility is in Hoxton, London, UK and its current products are:
• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;
• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:
The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of specialty critical care distributors.